REDWOOD CITY, Calif., April 05, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective March 31, 2022, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 461,000 shares of the common stock of the Company to newly hired employees with a per share exercise price of $12.91, the closing trading price on the grant date. One Chief level executive was granted options to purchase 200,000 shares as well as 50,000 restricted stock units. 18 non-officer employees were granted options to purchase an aggregate of 261,000 shares.
Read more at globenewswire.comProvided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.